Solvotrin Therapeutics sets sights on China

Solvotrin Therapeutics and Shanghai Fosun Pharmaceutical have agreed to enter into an exclusive distribution agreement for China with Solvotrin’s leading product, Active Iron.

Fosun Pharmaceuticals extensive distribution network across China will ensure that Active Iron can be made available through a variety of retail and ecommerce channels.

“This partnership is a perfect fit for Solvotrin we are delighted to work with a company who share in our of mission of improving human health. We look forward to finalizing this agreement in the coming months with the aim of making Active Iron available to the people of China in early 2019,” said Pat O’Flynn, CEO of Solvotrin.

Solvotrin Therapeutics is a privately held Irish healthcare and medicine development company based in Little Island Cork, focused on developing innovative science for significant unmet clinical needs. Solvotrin launched its first product Active Iron in 2016. This iron product was developed together with scientists at Trinity College Dublin. The groundbreaking formulation uses an innovative method of delivering iron which improves absorption and reduces side-effects.

The Active Iron range is designed to meet specific nutritional needs and includes a food for special medical purposes for patients with disease related malnutrition associated with iron. 2018 has seen global expansion for the Active Iron brand, with launches in Germany, New Zealand and the USA.

Read more:

Two medtech start-ups among Irish-Chinese trade deals worth €50m in major expo